Receptor affinity and potency of non-steroidal antiandrogens: Translation of preclinical findings into clinical activity

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 6, 1998, Pages 307-314

  Kolvenbag, G J C M ^a,b   Furr, B J A ^b   Blackledge, G R P ^b  

^a Zeneca Phrmaceuticals   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antiandrogen; Bicalutamide; Flutamide; Nilutamide; Prostate cancer

Indexed keywords

EID: 0000428935     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500262     Document Type: Article

References (80)

1. Huggins C, Hodges CV. Studies on prostatic cancer. 1. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
2. Debruyne FMJ, Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28: 177-188.
3. Kirby RS. Recent advances in the medical management of prostate cancer. Crit J Clin Pract 1996; 50: 88-93.
4. Veterans Administration Cooperative Urological Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011-1017.
5. Kaisary AV et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic cancer. Br J Urol 1991; 67: 502-508.
6. Goldenberg SL, Bruchowsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostate carcinoma. J Urol 1988; 140: 1460-1465.
7. Geller J. The role of adrenal androgens in prostate cancer. In: Pasqualini JR, Katzenellenbogen BS (eds). Hormone-Dependent Cancer. Marcel Dekker: New York, 1996, 289-305.
8. Bracci U, Di Silverio F. In: Role of cyproterone acetate in urology. Martini L, Motta M (eds). Androgens and Antiandrogens. Raven Press: New York, 1977, 333-339.
9. Labrie F et al. New hormonal therapy in prostate carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982; 5: 267-275.
10. Kaisary AV. Antiandrogen monotherapy in the management of advanced prostate cancer. J Urol 1997; 31 (Suppl 2): 14-19.
11. Barradell LB, Faulds D. Cyproterone: a review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994; 5: 59-80.
12. Drakos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992; 28A: 1932-1933.
13. Rabe T, Feldmann K, Grunwald K, Runnebaum B. Liver tumours in women on oral contraceptives. Lancet 1994; 334: 1568-1569.
14. Neri RO et al. Biological studies on an antiandrogen (SH 714). Eur J Pharmacol 1967; 1: 438-444.
15. Boccon-Gibod L et al. Flutamide versus orchidectomy in patients with metastatic prostate cancer. J Urol 1992; 147: 417A.
16. Denis LJ et al. Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trial (30853). Urology 1993; 42: 119-130.
17. Brogden RN, Chrisp P. Flutamide- a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer. Drugs Aging 1991; 1: 104-115.
18. Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155: 209-212.
19. Janknegt RA et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77-83.
20. Furr BJA et al. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen. J Endocrinol 1987; 113: R7-R9.
21. Kaisary AV. Current clinical studies with a new non-steroidal antiandrogen, Casodex. Prostate 1994; 5: 27-33.
22. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimen. Urology 1996; 47: 26-28.
23. Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology 1996; 47 (Suppl 1A): 13-25.
24. Kolvenbag GJCM, Blacklcdge GRP. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47: 70-79.
25. Kolvenbag GJCM, Furr BJA. Bicalutamide (Casodex) development: from theory to therapy. Cancer J 1997; 3: 192-203.
26. Kolvenbag GJCM, Blackledge GRP, Gotting Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate 1998; 34: 61-72.
27. Teutsch G et al. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem 1994; 48: 111-119.
28. Winneker RC, Wagner MM, Batzold FH. Studies on the mechanism of action of WIN49596: a steroidal androgen receptor antagonist. J Steroid Biochem 1989; 33: 1133-1138.
29. 3H]-cortisol binding to plasma proteins. J Steroid Biochem 1989; 33: 251-255.
30. Kemppainen JA, Wilson EM. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology 1996; 48: 157-163.
31. Luo S et al. Relative potencies of flutamide and Casodex preclinical studies. Eudocr Relat Cancer 1996; 3: 229-241.
32. Furr BJA. Relative potencies of flutamide and Casodex. Endocr Relat Cancer 1997; 4: 197-202.
33. Mukherjee A et al. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996; 26: 117-122.
34. Chandolia RK, Weinbauer GF, Behre HM, Nieschlag E. Evaluation of a peripherally selective antiandrogen (Casodex) as a tool for studying the relationship between testosterone and spermatogenesis in the rat. J Steroid Biochem Mol Biol 1991; 18: 367-375.
35. Chandolia RK, Weinbauer GF, Simoni M, Behre HM, Nieschlag E. Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and Casodex on the reproductive system of the male rat. Acta Endocrinologica 1991; 125: 547-555.
36. Gromoll J, Weinbauer GF, Simoni M, Nieschlag E. Effects of antiandrogens and ethane dimethane sulphonate (EDS) on gene expression, free subunits, bioactivity and secretion of pituitary gonadotrophins in male rats. Mol Cell Eudocrinol 1993; 91: 119-125.
37. Hamann LG et al. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-Dihydropyridono[5,6-g]quinolines. J Med Chem 1998; 41: 623-639.
38. Juniewicz PE et al. The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs. Endocrinology 1990; 126: 2625-2634.
39. Neri RO, Monahan M. Effects of a novel, non-steroidal anti-androgen on canine prostate hyperplasia. Invest Urol 1972; 10: 123-130.
40. Neri R, Florence K, Koziol P, von Cleave S. A biological profile of a non-steroidal antiandrogen, SCH 13521 (4′-nitro-3′-trifluoromethyllisobutyranilide). Endocrinology 1972; 91: 427-437.
41. Dhar JD, Setty BS. Effect of a non-steroidal antiandrogen, anandron, on the reproductive system and fertility in male rats. Contraception 1990; 42: 121-138.
42. Kager M, Spruß T, Schneider MR, von Angerer E. Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation. J Cancer Res Clin Oncol 1992; 118: 334-338.
43. Veldscholte J et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990; 173: 534-540.
44. Culig Z et al. Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy. Drugs Aging 1997; 10: 50-58.
45. Fenton MA et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 1383-1388.
46. Marchetti B, Labrie F. Characteristics of flutamide action on prostatic and testicular functions in the rat. J Steroid Biochein 1988; 29: 691-698.
47. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostatic cancer. Drugs Aging 1993; 3: 9-25.
48. Freeman SN, Mainwaring WIP, Furr BJA. A possible explanation for the peripheral selectivity of a novel non-steroidal pure anti-androgen, Casodex (ICI 176,334). Br J Cancer 1989; 60: 664-668.
49. Mahler C et al. Endocrine effects of 'Casodex'. A new non-steroidal antiandrogen. In: Murphy G, Khoury S (eds). Recent Advances in Urological Cancers. American Cancer Society: Atlanta, GA, 1990, 42-45.
50. McLeod DC. Tolerability of non-steroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.
51. Schellhammer P et al. Clinical benefits of bicalutamide (Casodex) versus flutamide (Eulexin) in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology 1997; 50: 330-336.
52. Cockshott ID et al. The pharmacokinetics of Casodex in prostatic cancer patients after single and during multiple dosing. Eur Urol 1990; 18: 10-17.
53. McKillop D et al. Metabolism and enantioselective pharmacokinetics of Casodex in man. Xenobiotica 1993; 23: 1241-1253.
54. Narayan P et al. A dose-response study of the effect of flutamide on benign prostatic hyperplasia: results of a multicenter study. Urology 1996; 47: 497-504.
55. Akaza H et al. Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. Int J Urol 1996; 3: 468-471.
56. Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31: 65-75.
57. Sogani PC, Vagaiwala MR, Whitmore VVF. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984; 54: 744-750.
58. Di Sil verio F et al. Experience with flutamide in advanced prostatic patients refractory to previous endocrine therapy. J Drug Dev 1987; 1 (Suppl 1): 10-16.
59. Pavone-Macaluso M et al. Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology 1989; 34 (Suppl 4): 27-36.
60. Prout GR et al. Long-term experience with flutamide in patients with prostatic carcinoma. Urology 1989; 34 (Suppl 4): 37-45.
61. Dccensi AU et al. Monotherapy with nilutamide, a pure non-steroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991; 146: 377-381.
62. Boccon-Gibod L et al. Flutamide versus orchidectomy in patients with metastatic prostate carcinoma, 11th Congress of the EAU 1994; Abstract 25.
63. Blackledge GRP. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Eur Urol 1996; 29 (Suppl 2): 96-104.
64. Chang A et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-2257.
65. Tyrrell CJ et al. A randomised comparison of Casodex 150mg versus castration in the treatment of advanced prostate cancer Proceedings of ASCO 15 May 1996, 1996; 15: 192 (Abstract 411).
66. Iversen P et al. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998; 51: 389-396.
67. Tyrrell CJ et al. A randomised comparison of Casodex (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-456.
68. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424.
69. Tyrrell CJ et al. A multicentre, randomized trial comparing the luteinising hormone releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. J Urol 1991; 146: 1321-1326.
70. Boccardo F et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. Eur J Cancer 1993; 29A: 1088-1093.
71. Crawford ED et al. Treatment of stage D2 prostate cancer with leuprolide and Anandron compared to leuprolide and placebo. In: Murphy G, Khoury S, Chatelain C, Denis L (eds). Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancers: Diagnosis and Treatment. SCI 1993, 61-63.
72. Fourcade RO et al. Zoladex plus flutamide versus Zoladex plus placebo in advanced prostatic carcinoma: extended follow-up of the French multicentre study. In: Murphy G, Khoury S, Chatelain C, Denis L (eds). Proceedings of the 3rd International Symposium on Recent Advances in Urological Cancers: Diagnosis and Treatment. SCI 1993, 102-106.
73. Iversen P, Rasmussen F, Klarskov J, Christensen IJ. Long term results of Danish prostatic cancer group trial 86. Goserelin acetate plus flutamide versus orchidectomy in advanced prostatic cancer. Cancer 1993; 72 (Suppl 12): 3851-3854.
74. Eisenberger MA et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042.
75. Schellhammer P et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996; 47 (Suppl 1A): 54-60.
76. Oosterlinck W et al. Tolerability and safety of flutamide in monotherapy with orchiectomy or with LHRHa in advanced prostate cancer patients. Eur Urol 1996; 30: 458-463.
77. Joyce R et al. High-dose bicalutamide for androgen-independent prostate cancer: effect of prior hormone therapy. J Urology 1998; 159: 149-153.
78. Scher HI et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15: 2928-2938.
79. Scher HI, Zhang ZF, Nantis D, Kelly VVK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47 (Suppl 1A): 61-69.
80. Schellhammer P et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157: 1731-1735.